Mohammad Sadegh Soltani-Zangbar

Mohammad Sadegh Soltani-Zangbar

Auto-generated profile, based on publicly available information

Mohammad Sadegh Soltani-Zangbar

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Iranian Biomedical Journal
Verified
Journal Article
Open access
PDF file
RJReza Jafari
Reza Jafari
NZNaime Majidi Zolbanin
Naime Majidi Zolbanin
JMJafar Majidi
Jafar Majidi
FAFatemeh Atyabi
Fatemeh Atyabi
MYMehdi Yousefi
Mehdi Yousefi
HRHoushang Rafatpanah
Houshang Rafatpanah
Background: Targeted co-delivery of siRNA and a chemotherapeutic drug is an attractive approach to cancer drug design and treatment. This study was carried out to design an anti-Mucin1 aptamer (Apt)-conjugated chitosan nanoparticle (NP) for targeted co-delivery of insulin-like growth factor receptor 1 (IGF-1R) Silencer siRNA and docetaxel (DTX) to SKBR3 cells. Methods: ...

1 October 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
SDShahla Danaii
Shahla Danaii
FGFarzaneh Ghorbani
Farzaneh Ghorbani
MAMajid Ahmadi
Majid Ahmadi
HAHossein Abbaszadeh
Hossein Abbaszadeh
LKLadan Koushaeian
Ladan Koushaeian
MYMehdi Yousefi
Mehdi Yousefi

16 July 2019 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
GSGolshan Sheikhansari
Golshan Sheikhansari
MSMohammad Sadegh Soltani‐Zangbar
Mohammad Sadegh Soltani‐Zangbar
ZPZahra Pourmoghadam
Zahra Pourmoghadam
AKAmin Kamrani
Amin Kamrani
RARamyar Azizi
Ramyar Azizi
MYMehdi Yousefi
Mehdi Yousefi

23 December 2022 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
NNNarjes Nouri
Narjes Nouri
OSOlduz Shareghi-Oskoue
Olduz Shareghi-Oskoue
LAleili Aghebati-Maleki
leili Aghebati-Maleki
SDShahla Danaii
Shahla Danaii
JHJavad Ahmadian Heris
Javad Ahmadian Heris
MYMehdi Yousefi
Mehdi Yousefi
Premature ovarian failure is a to some extent unknown and intricate problem with diverse causes and clinical manifestations. The lack of ovarian sex hormones presumably is effective in the occurrence of ovarian failure. Our progress in this field has been very little despite undertaken scientific research endeavors; scholars still are trying to understand the explanation of this dilemmatic medical condition. In contrast, the practice of clinical medicine has made meaningful strides in providing assurance to the women with premature ovarian insufficiency that their quality of life as well as long-term health can be optimized through timely intervention. Very recently Scientists have investigated the regulating effects of small RNA molecules on steroidogenesis apoptosis, ovulation, gonadal, and corpus luteum development of ovaries. In this literature review, we tried to talk over the mechanisms of miRNAs in regulating gene expression after transcription in the ovary.

1 April 2020 in Cytokine
Verified
Journal Article
Closed access
APAlireza Pishgahi
Alireza Pishgahi
RARozita Abolhasan
Rozita Abolhasan
SDShahla Danaii
Shahla Danaii
BABahareh Amanifar
Bahareh Amanifar
MSMohammad Sadegh Soltani-Zangbar
Mohammad Sadegh Soltani-Zangbar
MYMehdi Yousefi
Mehdi Yousefi

29 June 2020 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Open access
PDF file
APAlireza Pishgahi
Alireza Pishgahi
RARozita Abolhasan
Rozita Abolhasan
SSSeyed Kazem Shakouri
Seyed Kazem Shakouri
MSMohammad Sadegh Soltani-Zangbar
Mohammad Sadegh Soltani-Zangbar
SDShahla Dareshiri
Shahla Dareshiri
MYMehdi Yousefi
Mehdi Yousefi
Knee osteoarthritis (OA) is one of the common degenerative articular disorders that are related to decreased quality of life. Currently, novel biologic therapeutic approaches are introduced in the literature for OA management. In this study, the clinical efficiency of Dextrose prolotherapy, platelet-rich plasma (PRP) and autologous conditioned serum (ACS) injection on the level of pain and function in Knee OA were compared. A randomized clinical trial was directed on 92 knee OA patients. Patients were randomly divided into three groups: 30 were received dextrose prolotherapy once in a week for three weeks, 30 received autologous PRP for two times with seven days interval, and in the remaining 32 patients 2ml of ACS were injected two times every seven days. Study participants were measured through the Western Ontario and McMaster Universities (WOMAC) score, the visual analogue scale (VAS), at baseline, 1 and 6 months post-intervention. Both ACS and PRP treated patients showed improvement in pain intensity and knee function during 1 and 6 months pursue; however, this progress was more significant in the ACS group. Dextrose prolotherapy showed no substantial changes in pain and function of the affected knee in treated patients. Treatment of Knee OA with ACS and PRP injections are associated with pain reduction and knee function improvement. Not only, ACS therapy is more effective than that of PRP, but also due to its less variability in processing and less reported side effects, it could be considered as a safe and effective non-surgical alternative for OA management.